Tozorakimab exerts distinct dual pharmacology to reduce COPD epithelial remodelling - Amsterdam 2025

Biologics in action: clinical realities and translational innovations in airway disease therapeutics

Chair(s): Alexander Mathioudakis, Lies Lahousse

Session type: Oral presentation

Tozorakimab exerts distinct dual pharmacology to reduce COPD epithelial remodelling

Sam Strickson

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Sustained FEV1 improvements with mepolizumab up to 104 weeks in patients with COPD and less severe airflow obstruction: Post hoc analysis of the MATINEE Phase III study

Dave Singh

Replay

Poster

Abstract

Slides

Cardiovascular safety of biologicals in patients with asthma: a nationwide cohort study

Lies Lahousse

Replay

Poster

Abstract

Slides

Utility of CompEx as a component of clinical remission in NAVIGATOR

Guy Brusselle

Replay

Poster

Abstract

Slides

Exhaled nitric oxide (FeNO) predicts response to prednisolone for asthma attacks in patients on anti-IL5/5R? therapy

Imran Howell

Replay

Poster

Abstract

Slides

Efficacy of Dupilumab in Patients with Severe Asthma and Co-existing COPD

Sammy Adam Ameri

Replay

Abstract

Slides

Predicting Optimal Timing For Biologic Switch In Severe Asthmatic Patients

Enrico Schiavi

Replay

Abstract

Slides

Clinical characteristics associated with frequent asthma exacerbations whilst on treatment with tezepelumab

Faizan Haris

Replay

Abstract

Slides

Tozorakimab exerts distinct dual pharmacology to reduce COPD epithelial remodelling

Sam Strickson

Replay

Poster

Abstract

Slides

BBT002, a tetravalent bispecific antibody targeting human IL-4R? and IL-5, demonstrated synergistic efficacy in vitro and in a porcine pancreatic elastase (PPE)-induced COPD mouse model

Shanshan Xu

Replay

Poster

Abstract

Slides

Spatial Mapping of IL-4 / IL-13 and IL-4R? in COPD Lungs and Lymph Nodes

Jonas Erjefalt

Replay

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}